We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Test Rapidly Diagnoses Preeclampsia

By LabMedica International staff writers
Posted on 09 Aug 2017
Preeclampsia can lead to kidney damage in many affected women and the only therapy currently available is delivery of the baby, but this often means that infants are born prematurely and may have medical problems related to their early delivery.

More effective treatment strategies will depend on methods that would diagnose women with preeclampsia in a timely manner and a better understanding of preeclampsia’s underlying mechanisms. More...
Recent studies indicate that preeclampsia is linked with the abnormal presence in the urine of podocytes; however, available tests that can identify podocytes are expensive and time-consuming.

An international team of scientists collaborating with those at the Mayo Clinic, (Rochester, MN, USA) recruited at delivery a study population included 49 preeclamptic and 42 normotensive pregnant women. Plasma measurements included cell free fetal hemoglobin (HbF) concentrations and concentrations of the endogenous chelators haptoglobin, hemopexin, and α1- microglobulin. They assessed concentrations of urinary extracellular vesicles (EVs) containing immunologically detectable podocyte-specific proteins by digital flow cytometry and measured nephrinuria by an enzyme-linked immunosorbent assay (ELISA).

When the team compared the urine from women with normotensive pregnancies with urine from women with preeclamptic pregnancies, the latter contained a high ratio of podocin-positive to nephrin-positive urinary EVs (podocin+ EVs-to-nephrin+ EVs ratio) and increased nephrinuria, both of which correlated with proteinuria. Plasma levels of hemopexin, which were decreased in women with preeclampsia, negatively correlated with proteinuria, urinary podocin+ EVs-to-nephrin+ EVs ratio, and nephrinuria. They also found that fetal haemoglobin, which is normally present in pregnant women’s blood in small amounts, is present in higher amounts in pre-eclamptic women’s blood.

The authors concluded that their findings provide evidence that urinary EVs are reflective of preeclampsia-related altered podocyte protein expression. Furthermore, renal injury in preeclampsia associated with an elevated urinary podocin+ EVs-to-nephrin+ EVs ratio and may be mediated by prolonged exposure to cell free HbF.

Vesna D. Garovic, MD, a professor of Nephrology and Hypertension and the senior author of the study, said, “This increased amount of fetal haemoglobin in preeclampsia may be causing the release of podocyte fragments in the urine. We hope that this information will result in improved diagnostic procedures in women with pre-eclampsia; however, additional studies in larger numbers of patients and across different types of preeclampsia are needed.” The study was published on July 20, 2017, in the journal Clinical Journal of the American Society of Nephrology.

Related Links:
Mayo Clinic


New
Gold Member
Aspiration System
VACUSAFE
Online QC Software
Acusera 24•7
New
Automatic CLIA Analyzer
Shine i6000
New
Prefilled Tubes
Prefilled 5.0ml Tubes
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Roche’s CE-Marked Elecsys pTau217 blood test is a single‑assay blood test measures phosphorylated tau 217, an indicator of amyloid pathology and a hallmark of Alzheimer’s disease (image credit: Shutterstock)

Blood-Based Alzheimer’s Test Gains CE Mark for Amyloid Pathology Detection

Alzheimer’s disease is the most common cause of dementia, yet confirmatory testing remains invasive and hard to access. Diagnosis currently takes an average of 3.5 years, and about 75% of people with dementia... Read more

Molecular Diagnostics

view channel
Image: Clarifying tumor microenvironment features and cancer-cell programs linked to treatment response could provide earlier insight into triple-negative breast cancer therapy (image credit: Shutterstock)

Gene Panel Shows Promise for Predicting Chemotherapy Response in TNBC

Triple-negative breast cancer (TNBC) is an aggressive subtype commonly treated with chemotherapy, yet outcomes vary widely among patients. Understanding the tumor features that drive this variability remains... Read more

Microbiology

view channel
Image: The initiative combines epidemiological and microbiological data with whole-genome sequencing to characterize circulating hospital lineages and resistance determinants (image credit: Shutterstock)

Large-Scale Genomic Surveillance Tracks Resistant Bacteria Across European Hospitals

Antimicrobial resistance (AMR) poses a growing threat to patient safety, with carbapenem-resistant Enterobacterales causing difficult-to-treat infections and leaving clinicians with limited therapeutic options.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.